Namita Mohindra

Dr. Namita Mohindra

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
NSNeetu Soni
Neetu Soni
MOM. Ora
M. Ora
NMNamita Mohindra
Namita Mohindra
YMY. Menda
Y. Menda
GBG. Bathla
G. Bathla
SUMMARY: Tumor resection followed by chemoradiation remains the current criterion standard treatment for high-grade gliomas. Regardless of aggressive treatment, tumor recurrence and radiation necrosis are 2 different outcomes. Differentiation of tumor recurrence from radiation necrosis remains a critical problem in these patients because of considerable overlap in clinical and imaging presentations. Contrast-enhanced MR imaging is the universal imaging technique for diagnosis, treatment evaluation, and detection of recurrence of high-grade gliomas. PWI and PET with novel radiotracers have an evolving role for monitoring treatment response in high-grade gliomas. In the literature, there is no clear consensus on the superiority of either technique or their complementary information. This review aims to elucidate the diagnostic performance of individual and combined use of functional (PWI) and metabolic (PET) imaging modalities to distinguish recurrence from posttreatment changes in gliomas.

27 May 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
KHKasturi Hazarika
Kasturi Hazarika
RSRasmi Ranjan Sahoo
Rasmi Ranjan Sahoo
NMNamita Mohindra
Namita Mohindra
AWArchana Wakhlu
Archana Wakhlu
MMManesh Manoj
Manesh Manoj
AWAnupam Wakhlu
Anupam Wakhlu


12 November 2015 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
Durga Prasanna MisraDurga Prasanna Misra
Durga Prasanna Misra
ACAbhra Chandra Chowdhury
Abhra Chandra Chowdhury
HLHira Lal
Hira Lal
NMNamita Mohindra
Namita Mohindra
VAVikas Agarwal
Vikas Agarwal

13 September 2022 in Journal of Surgical Research
Verified
Journal Article
Closed access
NMNamita Mohindra
Namita Mohindra
NJNeeraj Jain
Neeraj Jain
MSMayilvaganan Sabaretnam
Mayilvaganan Sabaretnam
VAVinita Agrawal
Vinita Agrawal
PMPrabhakar Mishra
Prabhakar Mishra
GAGaurav Agarwal
Gaurav Agarwal

8 March 2023 in Acta Radiologica
Verified
Journal Article
Closed access
NMNamita Mohindra
Namita Mohindra
NJNeeraj Jain
Neeraj Jain
SYShubham Yadav
Shubham Yadav
VAVinita Agrawal
Vinita Agrawal
PMPrabhaker Mishra
Prabhaker Mishra
GAGaurav Agarwal
Gaurav Agarwal
Background: Tumor neo-angiogenesis plays an important role in the development and growth of breast cancers, but its detection by imaging is challenging. A novel microvascular imaging (MVI) technique, Angio-PLUS, promises to overcome the limitations of color Doppler (CD) in detecting low-velocity flow and small diameter vessels. Purpose: To determine the utility of the Angio-PLUS technique for detecting blood flow in breast masses and compare it with CD for differentiating benign from malignant masses. Material and Methods: A total of 79 consecutive women with breast masses were prospectively evaluated using CD and Angio-PLUS techniques, and biopsied as per BI-RADS recommendations. Vascular imaging scores were assigned using three factors (number, morphology, and distribution) and vascular patterns were divided into five groups: internal-dot-spot, external-dot-spot, marginal, radial, and mesh patterns. The independent samples t-test, Mann–Whitney U test, Wilcoxon signed rank test, or Fisher’s exact test were used to compare the two groups as appropriate. Area under the receiver operating characteristic (ROC) curve (AUC) methods were used to assess diagnostic accuracy. Results: Vascular scores were significantly higher on Angio-PLUS than CD (median=11, [IQR=9–13] vs. 5 [IQR=3–9], P < 0.001). Malignant masses had higher vascular scores than benign masses on Angio-PLUS ( P < 0.001). AUC was 80% (95% CI=70.3–89.7; P < 0.001) for Angio-PLUS and 51.9% for CD. Using Angio-PLUS at a cutoff value of ≥9.5, sensitivity was 80% and specificity was 66.7%. Vascular pattern descriptors on AP showed good correlation with histopathological results (PPV mesh 95.5%, radial 96.9%, and NPV of marginal orientation 90.5%). Conclusion: Angio-PLUS was more sensitive in detecting vascularity and superior in differentiating benign from malignant masses compared to CD. Vascular pattern descriptors on Angio-PLUS were useful.